Advances in Cancer Research

Erscheinungsjahr 2020
ISBN: 978-0-12-820327-9
Verlag: William Andrew Publishing

Buch, Englisch, 330 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 660 g

Advances in Cancer Research, Volume 148, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.

Zielgruppe

<p>Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.</p>

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Naturwissenschaften Biowissenschaften Virologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Epigenetic regulation of cancer stem cell and tumorigenesisKezhou Zhu, Victoria Xie and Suyun Huang2. Vascular mimicry: Triggers, molecular interactions and in vivo modelsStephen L. Wechman, Luni Emdad, Devanand Sarkar, Swadesh K. Das and Paul B. Fisher3. Biology, pathology, and therapeutic targeting of RASJ. Matthew Rhett, Imran Khan and John P. O'Bryan4. Cyclin D-CDK4/6 functions in cancerXueliang Gao, Gustavo W. Leone and Haizhen Wang5. SPARC-p53: The double agents of cancerDenise Camacho, Joana P. Jesus, António M. Palma, Sofia A. Martins, Alexandre Afonso, Maria Leonor Peixoto, Christopher J Pelham and Rajan Gogna6. Giants and monsters: Unexpected characters in the story of cancer recurrence Shai White-Gilbertson and Christina Voelkel-Johnson7. Ca2+ as a therapeutic target in cancer Scott Gross, Pranava Mallu, Hinal Joshi, Bryant Schultz, Christina Go and Jonathan Soboloff

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.